Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/89178
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Industrial and Systems Engineering-
dc.creatorTang, Y-
dc.creatorXiao, Z-
dc.creatorPan, L-
dc.creatorZhuang, D-
dc.creatorCho, KS-
dc.creatorRobert, K-
dc.creatorChen, X-
dc.creatorShu, L-
dc.creatorTang, G-
dc.creatorWu, J-
dc.creatorSun, X-
dc.creatorChen, DF-
dc.date.accessioned2021-02-04T02:40:01Z-
dc.date.available2021-02-04T02:40:01Z-
dc.identifier.urihttp://hdl.handle.net/10397/89178-
dc.language.isoenen_US
dc.publisherFrontiers Research Foundationen_US
dc.rightsCopyright © 2020 Tang, Xiao, Pan, Zhuang, Cho, Robert, Chen, Shu, Tang, Wu, Sun and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en_US
dc.rightsThe following publication Tang, Y., Xiao, Z., Pan, L., Zhuang, D., Cho, K. -., Robert, K., . . . Chen, D. F. (2020). Therapeutic targeting of retinal immune microenvironment with CSF-1 receptor antibody promotes visual function recovery after ischemic optic neuropathy. Frontiers in Immunology, 11, 585918, 1-15 is available at https://dx.doi.org/10.3389/fimmu.2020.585918en_US
dc.subjectColony stimulating factor-1en_US
dc.subjectMicrogliaen_US
dc.subjectNeurodegenerationen_US
dc.subjectPositive scotopic threshold responseen_US
dc.subjectRetinal ganglion cellen_US
dc.subjectRetinal ischemia/Reperfusionen_US
dc.subjectVisual acuityen_US
dc.titleTherapeutic targeting of retinal immune microenvironment with CSF-1 receptor antibody promotes visual function recovery after ischemic optic neuropathyen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.spage1-
dc.identifier.epage15-
dc.identifier.volume11-
dc.identifier.doi10.3389/fimmu.2020.585918-
dcterms.abstractRetinal ischemia/reperfusion injury (RI) is a common cause of irreversible visual impairment and blindness in elderly and critical unmet medical need. While no effective treatment is available for RI, microglial activation and local immune responses in the retina are thought to play important roles in the pathophysiology of neurodegeneration. While survival and activation of microglia depend critically on colony-stimulating factor receptor (CSF-1R) signaling, it remains unclear if targeting the retinal immune microenvironments by CSF-1RAb after RI is sufficient to rescue vision and present a potentially effective therapy. Here we used rodent models of RI and showed that retinal ischemia induced by acute elevation of intraocular pressure triggered an early activation of microglia and macrophages in the retina within 12 h. This was followed by lymphocyte infiltration and increased production of pro-inflammatory cytokines. Intravitreal injection of CSF-1R neutralizing antibody (CSF-1RAb) after RI significantly blocked microglial activation and the subsequent T cell recruitment. This also led to improved retinal ganglion cell survival and function measured by cell quantification and electroretinogram positive scotopic threshold responses, as well as increased visual acuity and contrast sensitivity as assessed by optomotor reflex-based assays, when compared to the isotype-treated control group. Moreover, the administration of CSF-1RAb efficiently attenuated inflammatory responses and activation of human microglia in culture, suggesting a therapeutic target with human relevance. These results, together with the existing clinical safety profiles, support that CSF-1RAb may present a promising therapeutic avenue for RI, a currently untreatable condition, by targeting microglia and the immune microenvironment in the retina to facilitate neural survival and visual function recovery.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationFrontiers in immunology, Nov. 2020, v. 11, 585918, p. 1-15-
dcterms.isPartOfFrontiers in immunology-
dcterms.issued2020-11-
dc.identifier.isiWOS:000592437300001-
dc.identifier.scopus2-s2.0-85096785424-
dc.identifier.pmid33281816-
dc.identifier.eissn1664-3224-
dc.identifier.artn585918-
dc.description.validate202101 bcrc-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Scopus/WOSen_US
dc.description.pubStatusPublisheden_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
fimmu-11-585918.pdf4.73 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

73
Last Week
0
Last month
Citations as of May 12, 2024

Downloads

19
Citations as of May 12, 2024

SCOPUSTM   
Citations

13
Citations as of May 16, 2024

WEB OF SCIENCETM
Citations

14
Citations as of May 16, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.